propiverine has been researched along with Adverse Drug Event in 1 studies
propiverine: anticholinergic used for overactive bladder syndrome
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oxybutynin 15 mg was more effective than propiverine 20 mg in reducing symptomatic and asymptomatic IDCs in ambulatory patients." | 2.72 | Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. ( Abrams, P; Cardozo, L; Chapple, C; Hargreaves, K; Khullar, V; Serdarevic, D, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, P | 1 |
| Cardozo, L | 1 |
| Chapple, C | 1 |
| Serdarevic, D | 1 |
| Hargreaves, K | 1 |
| Khullar, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population[NCT02385500] | Phase 4 | 5 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to Insufficient or untimely patient recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for propiverine and Adverse Drug Event
| Article | Year |
|---|---|
Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
Topics: Benzilates; Cross-Over Studies; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions | 2006 |